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Abstract
We have developed the first immature large animal translational treatment trial of a pharmacologic
intervention for traumatic brain injury (TBI) in children. The preclinical trial design includes multiple doses
of the intervention in two different injury types (focal and diffuse) to bracket the range seen in clinical
injury and uses two post-TBI delays to drug administration. Cyclosporin A (CsA) was used as a case study
in our first implementation of the platform because of its success in multiple preclinical adult rodent TBI
models and its current use in children for other indications. Tier 1 of the therapy development platform
assessed the short-term treatment efficacy after 24 h of agent administration. Positive responses to
treatment were compared with injured controls using an objective effect threshold established prior to the
study. Effective CsA doses were identified to study in Tier 2. In the Tier 2 paradigm, agent is administered
in a porcine intensive care unit utilizing neurological monitoring and clinically relevant management
strategies, and intervention efficacy is defined as improvement in longer term behavioral endpoints above
untreated injured animals. In summary, this innovative large animal preclinical study design can be
applied to future evaluations of other agents that promote recovery or repair after TBI.
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Abstract
We have developed the first immature large animal translational treatment trial of a pharmacologic
intervention for traumatic brain injury (TBI) in children. The preclinical trial design includes
multiple doses of the intervention in two different injury types (focal and diffuse) to bracket the
range seen in clinical injury and uses two post-TBI delays to drug administration. Cyclosporin A
(CsA) was used as a case study in our first implementation of the platform because of its success
in multiple preclinical adult rodent TBI models and its current use in children for other
indications. Tier 1 of the therapy development platform assessed the short-term treatment efficacy
after 24 h of agent administration. Positive responses to treatment were compared with injured
controls using an objective effect threshold established prior to the study. Effective CsA doses
were identified to study in Tier 2. In the Tier 2 paradigm, agent is administered in a porcine
intensive care unit utilizing neurological monitoring and clinically relevant management
strategies, and intervention efficacy is defined as improvement in longer term behavioral
endpoints above untreated injured animals. In summary, this innovative large animal preclinical
study design can be applied to future evaluations of other agents that promote recovery or repair
after TBI.
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INTRODUCTION
Head injury is the leading cause of death and disability in children (38), and unfortunately
there are only general management guidelines (3). While only a modest number of pediatric
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clinical trials for traumatic brain injury (TBI) have been conducted (1, 39, 42, 61, 66, 93),
nearly all pediatric trials and over 100 adult TBI trials (9, 14, 56, 71) have failed to show
significant neuroprotective benefits of any pharmacologic therapy.
While general care principles have improved outcomes, specific neuroprotective
interventions are extremely limited. The heterogeneity of TBI, with distinct
pathophysiologies and mechanisms associated with contusions, hemorrhages and diffuse
axonal injuries, added to a panoply of variable host factors, likely contributes to the
recurrent failure of large head injury treatment trials (60, 74). In children, the immature
brain response to each type of TBI changes rapidly during development from infancy
through adolescence (7, 20, 22, 68). Therefore, the development of head injury therapies for
acute brain injury in children requires appropriate immature animal models in which to test
potential treatments. Rodents are limited as models for human children because of marked
differences in maturation, morphology and injury mechanisms (17). Therefore, treatments
developed in adult rodents might be ineffective, or even contraindicated, in human children.
Motivated by the need for appropriate immature animal models, our collaborating
laboratories have developed, well-characterized and thoroughly tested immature swine
models for TBI research for more than 15 years (20, 21, 24, 29, 51, 59, 68, 69, 77, 81).
These models mimic the spectrum of TBI observed in infants and children. The purely
inertial (nonimpact) rotation model creates diffuse axonal injury and subarachnoid
hemorrhage, and the purely focal model creates a localized cortical and subcortical
contusion (Figure 1). By using both models, we have characterized the response of the
immature brain at the two endpoints of the focal-to-diffuse and cortical surface to axonal
white matter injury spectrum. To characterize changing injury responses in the maturing
brain, we have studied different developmental stages, infancy through adolescence, in both
piglet models. From these studies, we have determined that the 1-month age (“toddler”)
piglet has unique characteristics that reflect pathophysiology similar to the preschool and
early childhood stage in human children. At this age, cerebral blood flow (CBF) is maximal,
brain swelling is the most pronounced, and other injury responses are similar to the unique
findings seen in young human children (19, 20, 23).
We have designed an innovative, state-of-the-art preclinical study platform to create a
translational bridge between basic science discoveries in the rodent and randomized control
trials for TBI in children. Our preclinical study was led by a collaborative team of pediatric
TBI experts able to measure the pharmacokinetics (PK) and the short- and long-term
pharmacodynamic response to treatment for TBI. To duplicate the human clinical setting,
the platform incorporates the best contemporary pediatric neurocritical care management
and monitoring strategies to enhance translation to clinical trials. Using our wellcharacterized, reproducible and clinically relevant immature porcine TBI models, we
employed well-developed assessments of physiologic, biochemical and cognitive/behavioral
outcomes that we believe surpass rodent models for their fidelity to children to determine
the optimal evidence-based dosing strategy for a future large randomized controlled trial for
treatments in children with TBI.
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Because mitochondria play a critical role in many primary and secondary pathologic
pathways in TBI, cyclosporin A (CsA), which inhibits opening of the mitochondrial
permeability transition pore, was used as a case study in our first implementation of the
platform. Because of its safety profile in humans, pleiotropic effects and success in multiple
preclinical adult rodent TBI models, CsA was selected for its multifaceted potential as an
effective therapy for pediatric TBI. Because CsA was also off-patent and already in use in
children for other indications, the results of the preclinical therapy development plan could
be translated rapidly and inexpensively to clinical trial.

METHODS
Animal model selection
We have used our established immature porcine TBI models, controlled cortical impact
(CCI) and rapid nonimpact rotation (RNR), to produce the spectrum of pathophysiology
seen in mild to severe TBI in the child, from infancy to early adolescence. The CCI (Figure
1) model utilizes a skull-mounted, spring-loaded blunt indentation device to create a rapid (4
ms) displacement of the cortical surface, producing a focal cortical contusion, with
underlying white matter damage, decreased CBF and somatosensory dysfunction (19–21).
This model was designed to produce a specific injury type, focal contusion, which is one of
the most common types of brain injury in children and results most often from falls,
recreational and sports injuries, and vehicular trauma (34, 46, 82). Because the displacement
of the cortex is coupled to the skull, this model produces no inertial motion of the head
itself, and in this way embodies a purely focal injury mechanism. The model creates a welldefined cortical and subcortical contusion with variable hemorrhage which evolves over
time, is associated with regional brain swelling and changes in blood flow, and can be
measured by histology or imaging. The contusion is placed in the rostral gyrus, which is the
somatosensory cortex subserving snout sensation. The injury is not associated with
immediate changes in consciousness or gross motor deficits. At the other end of the injury
spectrum, to create a purely inertial injury, the RNR model produces a high magnitude
acceleration/deceleration, similar to that experienced in motor vehicle or high velocity
trauma, but with no impact event, and utilizes a single rapid (12–20 ms), sagittal head
rotation (Figure 1). This injury mechanism produces unconsciousness, sustained cognitive
dysfunction, bilateral diffuse axonal and hemorrhagic injury; and marked decreases in global
CBF, brain tissue oxygen content (PbtO2) and alterations in mitochondrial function (24, 29,
68). Our goal was to inform a clinical study with injury-specific optimal dosing strategies by
evaluating treatment effectiveness over the spectrum of injury types.
Based on our prior studies of brain development and age-dependent injury responses, the 4week-old piglet is similar to human children at the toddler/preschool age (17, 18, 20, 23,
57). Age-specific responses are attributable to maturational differences in brain mass,
stiffness, deformation tolerance and biological responses. The toddler age in the child was
chosen for our first test of this large animal model platform for therapeutic development
because it is an age with physiologically important and maximal developmental differences
in myelination, apoptotic pathways, glutamatergic receptor mechanisms, synaptogenesis and
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CBF responses compared with adults. The toddler piglet mimics the range of measureable
post-TBI morbidity seen in the human toddler and young child.
Therapy development plan overview
Recent workshops of the TBI and stroke scientific communities have examined why agents
with preclinical therapeutic efficacy have failed to translate to clinical success (15, 27, 36,
50). They concluded that agents should be tested in multiple species using clinically relevant
outcomes, short-term and long-term endpoints, histological and functional metrics, and
include clinical management strategies (45). We conducted our therapy development studies
across multiple laboratories, while including current pediatric TBI critical care management
protocols, clinically relevant physiological monitoring, and realistic injury-to-treatment
intervals of 1 and 6 h after TBI, to mimic urban and rural time to implantation of therapy.
Treatments were administered intravenously (IV) for 24 h via an ambulatory wireless
programmable infusion pump, delivering a loading dose followed by continuous infusion to
achieve target concentrations rapidly and to sustain exposure, similar to current clinical
studies for adult TBI (54). The platform employs a two-tiered funnel approach: focusing
first on multiple short-term (24 h) endpoints—histological and cellular bioenergetic
measures—to identify dosing strategies with a reproducible, robust efficacy, followed by
studies evaluating sustained cognitive benefits. Importantly, the platform includes obtaining
microdialysate samples and blood for serum biomarkers, currently unconfirmed clinical
intensive care readouts in children, and in future secondary analyses we plan to correlate
them with direct measures (mitochondrial function and pathology) and neurofunctional
behavior. These analyses, which are an important feature of our preclinical development and
optimization plan, will accelerate the translation to a rational clinical trial design, informing
the monitoring and management strategy, as well as inclusion criteria. Finally, although we
recognized the potential for inflation of type I error through the multiple experiments
utilized in the platform, the use of efficient factorial design in combination with the overall
sequenced study design was created to optimize identification of promising treatments in an
important clinical area with no effective pharmacologic interventions. In summary, this
state-of-the-art, innovative preclinical study design will be applied to future evaluations of
other agents that promote recovery or repair after TBI, other ages, combination therapies and
other types of TBI.
In the first tier of our Therapy Development Plan, we evaluated the tolerability and efficacy
of the therapeutic agent to identify two promising doses for each injury type (diffuse, focal)
and post-TBI treatment start times (1 and 6 h) based on terminal endpoints of
neuroprotective effectiveness at 24 h. In the second tier, the optimum dose for each injury
type and start time with the best 6-day cognitive outcomes is identified. In Tier 1, for each
start time and injury type, both the most effective dose and the lowest dose that achieve a
significant effect advance to Tier 2 for further study. In Tier 2, not yet conducted, these two
doses for each start time and injury type are assessed for their efficacy in neurocognitive
outcomes, measured 6 days after injury, to identify the optimal dosing strategy to evaluate in
clinical trials. Later studies will identify PK, toxicology responses and sex-specific cognitive
recoveries to the therapeutic dosing strategy and injury type that showed the best cognitive
recovery in Tier 2.
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As a proof-of-translation study, we used the immature large animal model platform as a
preclinical study to evaluate the effectiveness of agents with a demonstrated track record of
efficacy in adult rodent focal neural injury models and an established safety profile in
children. Additional considerations may also be that the agent is in therapeutic use or
clinical trials for other indications in adults and children, enhancing rapid translation to a
clinical trial. We selected CsA as our case study, and our rationale for agent selection is
discussed in the next section.
Agent selection
TBI processes, including contusion, diffuse or focal axonal injury, hematomas, and
subarachnoid hemorrhage (1, 2, 58, 74), can initiate ischemia, edema, inflammation, tissue
shifts and brain herniation (9). Subsequent cellular and molecular responses progress over
minutes, hours and days to mediate progressive cellular damage (50, 52, 65, 67, 76, 95),
decreased CBF and mitochondrial disturbances (35, 52, 65, 80, 91, 97). A growing body of
literature suggests that mitochondria play a key role in many pathologic pathways in
neurodegenerative disorders, focal/global ischemia and trauma (48, 73, 75). Mitochondrial
dysfunction leads to energy imbalance, ionic imbalance, release of cytochrome c,
proapoptotic events, mitochondrial swelling and reduced brain ATP levels (86).
Following pediatric TBI, mitochondrial dysfunction is involved in excitotoxicity, oxidative
stress, metabolic perturbations and, ultimately, cell death (73). It is difficult to extrapolate
adult TBI data to pediatric models because critical mitochondrial characteristics such as the
number and density of complexes of the electron transfer chain, antioxidant enzyme activity
and content, and lipid content are very different between young and adult animals (8, 16).
To our knowledge, no investigators have tested potential mitochondria-targeted
neuroprotective therapeutic strategies in a large animal model of pediatric TBI.
CsA inhibits progressive mitochondrial dysfunction by stabilizing the mitochondrial
transition pore (87). Preclinical TBI and ischemia CsA studies (mostly in rodents) have
demonstrated neuroprotection using immunohistochemistry, isolated mitochondrial
preparations and behavioral tests (6, 25, 28, 30, 37, 47, 78, 83, 87). The advantages of CsA
are that it is FDA approved, off-patent, inexpensive and thought to have well-described
safety and dosing profiles. In January 2015, there were 109 open clinical trials using CsA in
children for indications other than brain injury. In a TBI Phase I clinical trial in adults, CsA
satisfied a broad range of safety parameters (54), but no Phase II or III trial is in progress
(53). Although CsA has delayed brain penetration and its chronic usage adversely impacts
the immune system, we may avoid similar immunological concerns when CsA is limited to a
short period, such as for acute TBI treatment. In summary, because of its safety profile in
humans, multimodal pharmacological effects, and success in multiple preclinical rodent
models of brain injury, CsA has potential as a therapeutic agent for neuroprotection in
children after TBI. We hypothesized that CsA would inhibit mitochondrial dysfunction and
decrease axonal and neuronal injury within 24 h after head trauma, and would promote
longer term neurological functional recovery. Our objective was to obtain data on the PK
and pharmacodynamics of CsA in two established immature large animal preclinical models
to provide evidence-based dosing guidance for a future large randomized controlled trial for
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CsA in children. Our central hypothesis is that safe, therapeutic concentrations of CsA could
improve outcomes for children who have sustained TBI.
Dosing rationale—allometric scaling across species
Tier 1 dose selection is based on published rodent neuro-injury (6, 55, 87), our previous data
in the infant piglet (44), published dosing guidelines, and Phase I–IV clinical trials. Rather
than scaling the dose across species normalizing by body weight, more recent PK literature
advocates the extrapolation of rat dose to pig and human doses be performed through
normalization to body surface area using the Km factor and the following formula: dose for
animal x in mg/kg equals the dose in animal y in mg/kg times (Kmy/Kmx) (70), where the
estimated Km for the rat, 4-week-old piglet, human child and adult are 6, 20, 25 and 37,
respectively. First, CsA was studied in an adult rat model of focal TBI, and a U-shaped
dose-response was observed (6, 55, 87), such that the most beneficial dose was determined
to be 20 mg/kg/day divided in two 10 mg/kg doses (87). Using relevant allometric Km, this
optimal rat dose translates into 6 mg/kg/day in the pig and 3.3 mg/kg day in the human
adult. Second, CsA is being used clinically in the human in doses between 5 and 21
mg/kg/day (32, 49, 54), which translate into “safe” doses of 9.25 and 39 mg/kg/ day in the
pig and 30 and 126 mg/kg/day in the rat. Third, in the infant piglet, we have conducted pilot
studies (N = 4–5/group) and found that an IV bolus of CsA (20 mg/kg) given 5 min and
again at 12 h after RNR TBI (totaling 40 mg/kg/day) markedly reduced lesion volume and
lactate-pyruvate ratios 24 h after TBI, with increased CBF and mitochondrial respiratory
control ratio (RCR) in hippocampus, olfactory, cortex and cerebellum, compared with
saline-treated injured piglets. Given the U-shaped pharmacodynamics of CsA (85), the
toxicity data from humans, and effective doses in rat and piglet, we investigated four CsA
doses higher and lower than our infant piglet studies: 10, 20, 40 and 60 mg/kg/day for Tier 1
optimization studies, given toxicity data in humans and doses deemed effective in the rat and
piglet. Based upon human TBI clinical trials, rodent CCI and porcine RNR studies,
treatment duration was 24 h for all tiers. The half-life of CsA is long, approximately 18 h in
newborn pigs and 7 h in mature pigs (92), and steady state exposure cannot be reached
during a 24-h treatment duration. A rapid loading dose can achieve therapeutic
concentrations faster, but plasma CsA levels may exceed tolerable concentrations (26, 84).
Renal tolerance limits in the pig are 9 mg/kg IV over 1 h (13), but higher loading doses have
not been studied and may be tolerated. In summary, based on CsA half-life, published CsA
pig clearance rates and tolerance, and the current human clinical trials employing continuous
IV infusion, the 24-h dose strategy was to be divided into a 1-h IV loading infusion to reach
target concentrations rapidly, with the remainder delivered in a 23-h continuous IV infusion
for sustained exposure, with a ratio (in mg/kg) of 0.32 between load and infusion doses.
Because the 40 and 60 mg/kg/day dose will exceed 9 mg/kg in the loading period, and no
data are available for piglets, future toxicology studies should be performed should those
higher doses prove effective.
Agent-specific evaluation metrics for screening in Tier 1
Tier 1 was the short-term (24-h) evaluation of the CsA dose-response of traumatic braininjured piglets. Treatment efficacy was evaluated using two terminal endpoints,
neuropathology and mitochondrial function, in animals sacrificed at 24 h after treatment was
Brain Pathol. Author manuscript; available in PMC 2016 May 01.
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initiated. Our rationale for using mitochondrial function, specifically maximal coupled
respiration (RCR), as a criterion for positive outcome effectiveness is that previous studies
demonstrated that RCR decreases within hours after TBI, remains impaired days later, and
its early rescue with mitochondrial protectant CsA correlates with cognitive benefits at 7
days after injury (11, 55, 79). In infant piglets (3–5 days old) treated with 40 mg/kg/day CsA
IV divided into two injections post-RNR, reductions in RCR were inhibited and maintained
at sham levels (44). Similarly, we selected lesion volume (Vinj) at 24 h post-TBI as a second
positive outcome metric based upon prior studies which demonstrated that after CCI in the
piglet brain lesion volume is near maximal around 24 h after injury (19), and that injured
volume was reduced by 42% in the RNR-injured infant animals treated with 40 mg/kg/day
CsA IV (44).
When we designed the Tier 1 study as a screening paradigm, we understood that the
variability of the underlying condition in genetically heterogeneous subjects would require
very large animal group sizes (and prohibitively high costs) to identify effect magnitude and
formulate a dose–response curve. Thus, cost considerations restricted our study design,
making comparisons of size of effect across doses untenable. Therefore, using clinical trials
with multiple “success metrics” as our guide, in our analysis we defined positive outcome
“thresholds” for pathology and mitochondrial function, and enhanced our statistical power
by combining the results from these two sets of animals by determining a total “positive
outcome” rate. Consequently, Tier 1 was designed as a screening paradigm to select
promising doses for Tier 2 based on the combination of two metrics. As such, the efficacy
analysis is not based upon the absolute treatment effect size (lesion size or mitochondrial
function); instead, the analysis is based upon achievement of a clinically significant greater
number of “positive outcomes” with treatment compared with untreated injured subjects.
The definitions of “clinically significant” alterations to mitochondrial function and
neuropathology were determined by pilot series to obtain thresholds prior to evaluation of
the experimental data. Based on criteria discussed in the next two sections, each subject was
classified as either a “neuropathology lesion volume positive outcome” or “mitochondrial
function positive outcome.” Efficacy was defined when ≥30% more of the N = 20 animals in
a CsA dose/time/model group had a combined positive outcome (based upon mitochondrial
function and neuro-pathology) compared with injured time/model controls receiving only
saline. This is a very ambitious threshold to identify promising therapies as a consequence of
budgetary constraints dictating small study cohort sizes.
Because it is postulated that the optimal dose may vary with injury-to-treatment interval and
between focal and diffuse injuries, each post-injury start time and each injury type were
analyzed independently (four groups: 1-h delay to treatment initiation CCI, 6-h CCI, 1-h
RNR, 6-h RNR). For each group, all doses that met the efficacy criteria were eligible to
move forward to Tier 2 experiments to determine longer term neurofunctional outcomes.
However, the platform was designed so that if multiple doses for a post-injury start time
showed efficacy at the end of Tier 1, a maximum of two doses for each start time/injury-type
group would move forward to Tier 2, the dose with the highest success rate (“greatest
neuroprotection”) and the lowest dose that meets the success criterion for demonstrating a
successful neuroprotective effect, to potentially limit the side-effect profile. Furthermore, if

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 8

we found a tie for two doses with the highest success rate at an administration time for a
given model, we would select the dose that has the highest magnitude of positive outcome.
The maximum number of dose-model-treatment time combinations moving forward from
Tier 1 to Tier 2 would be 8 (2 doses × 2 models × 2 delays to treatment) plus normative
controls, a dramatic reduction from the total number across all of the dosing groups studied
in Tier 1. This strategy was chosen as a practical way to limit the trial animal and resource
utilization and expense.
Pathology threshold for positive outcome
To judge effectiveness in Tier 1 screening, we had to determine a threshold for each
surrogate outcome measure (pathology and mitochondrial energetics) that would be used to
designate a subject as showing a likely effect of CsA. We defined a subject classified as
showing a clinically significant “positive outcome” for the pathology effectiveness metric as
an animal with a reduction in lesion volume that is large compared with the distribution
found in the saline-treated (vehicle) animals with the same injury type. To accomplish this,
we determined the mean and standard deviation of the lesion volumes in a relevant injurymatched vehicle group (CCI or RNR) generated prospectively prior to the Tier 1
experiments and established a threshold of 0.85 times the standard deviation (0.85*stdev)
less than this vehicle group mean. Because of small but potentially meaningful differences
in the specific CCI devices and the rotational velocities used in the injuries between the first
and second years of the Tier 1 study, we determined a pathology threshold that was unique
to each year. Therefore, each treated (and vehicle) animal was evaluated against the relevant
“positive outcome” threshold to determine pathology positive outcome rates for every dose/
time/model group. Importantly, this bar was more demanding (larger injury reduction
required to be considered a “positive outcome”) when the injury volume was more variable
in our vehicle control group. In fact, this objectively derived pathology threshold established
that a reduction in lesion volume of 21%–58% was required for a CsA-treated animal to be
considered a positive outcome (across all TBI models, times and years), averaging 25% in
the RNR groups and 50% in the CCI groups—a dramatic reduction in pathology. The total
number of “Pathology positive outcomes” is provided in the Results (Table 2). In short, for
each model, defining the threshold for a positive outcome as the mean +0.85*stdev of the
untreated injured group set the “positive outcome” rate at 20% of the untreated injured
vehicle controls. We found that the treatment groups had positive outcome rates of 0%–
60%.
Mitochondrial threshold for positive outcome
For diffuse brain injury, we defined the mitochondrial functional threshold for positive
outcome as the RCR measured in isolated mitochondria greater or equal to 5 (after
combining results from the cortex and hippocampal regions) based upon our own prior data
in the RNR model (44). Historically, a single RCR value is rarely used to define an injury
threshold for focal TBI models. Rather, RCR in the ipsilateral injured side is typically
compared with a benchmark value, for example, RCR in the contralateral side in the same
animal, ipsilateral side in sham controls, or the ipsilateral side in treated injured animals.
Moreover, our extensive review of the animal literature on this specific aspect of
mitochondrial functional assessment reveals that the RCR on the ipsilateral injured side can
Brain Pathol. Author manuscript; available in PMC 2016 May 01.
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vary considerably, lab to lab, justifying the use of comparative benchmark ratios for focal
brain inju ries, usually the contralateral side in the same animal, thus generating an RCR
ratio. We generated a separate set of (N = 5) untreated CCI piglets to define the positive
outcome threshold for the mitochondrial function metric. Not surprisingly, the mean
ipsilateral : contralateral RCR ratio of this untreated injured piglet group (mean ± stdev, 0.55
± 0.33) was significantly lower than those from N = 7 uninjured shams (1.04 ± 0.46, P =
0.03). As with the pathology positive outcome threshold, we used the mean and standard
deviation (stdev) of our untreated CCI group to define an objective threshold for a positive
outcome as 0.85stdev greater than the mean untreated value. Specifically, a positive
outcome was an RCR ipsilateral/contralateral ratio value ≥0.83, derived as the mean RCR
ratio of untreated injured controls plus 0.85 times the standard deviation, or 0.55 + (0.85)
(0.33) = 0.83.
Tier 1 studies were conducted over 2 years. In year 2, for the second half of the Tier 1
studies, we took advantage of rapidly evolving technological developments in mitochondrial
assessment to provide a more robust evaluation of mitochondrial function. We made three
improvements in our measurements of mitochondrial respiration. First, we transitioned from
tissue mitochondrial isolation techniques to new protocols developed to utilize tissue
homogenates for mitochondrial respiration. Homogenates potentially have several
advantages over isolated mitochondria preparations: reduced disruption of intracellular and
intercellular signaling pathways (94), preservation of mitochondrial structure and function
(63, 64), and decreased mitochondria population loss, which may be >60% with isolation
techniques (62). Thus, homogenates may provide a more relevant and reliable assessment of
in vivo function. As a second technological improvement in year 2, we upgraded our
traditional Clark-type oxygen electrode (Hansatech Instruments, Norfolk, UK) that measures
oxygen consumption in nmols to a more sensitive instrument (Oxygraph-2K, OROBOROS
Instruments, Innsbruck, Austria) that measures oxygen consumption in pmol, providing a
more consistent and nuanced readout of mitochondrial respiration. Third, we upgraded our
respiration protocol by adding the substrate succinate to allow us to measure oxidative
phosphorylation via integrated convergent complex I and II electron flow (33), whereas our
year 1 standard respiration protocol only utilized NADH-linked substrates (pyruvate +
malate).
We therefore generated an additional set of benchmark untreated sham (N = 20) and injured
(CCI or RNR N = 20) animals. We confirmed that RCR ≤5 still distinguished RNR-injured
animals from shams, but while the ipsilateral to contralateral ratio of total oxidative
phosphorylation was similar after these technological enhancements, the ratio measurement
now had less variability. Specifically, the untreated CCI total oxidative phosphorylation
ipsilateral to contralateral ratio was 0.61 ± 0.15, yielding a positive outcome defined as a
ratio ≥0.73. In parallel manner to the evaluation of positive outcomes for pathology, CCI
animals in year 1 were evaluated against the year 1 threshold, and those in year 2 were
evaluated against the year 2 CCI threshold. The total number of “Mitochondrial function
positive outcomes” is provided in Table 2. For each model, about 35% of the vehicle
controls met the criteria to be designated as spontaneous “positive outcomes,” while the
treatment groups had mitochondrial functional positive outcome rates of 30%–70%.
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Statistical considerations
Power calculations were performed to determine the minimal difference that can be detected
with the proposed sample size of 20/group in Tier 1 and 30/group in Tier 2. We assume onesided α = 0.05 and 80% power; one-sided tests were chosen to identify potentially
efficacious strategies. For binary outcomes such as positive outcome rates, Table 1 shows
the detectable rate differences, based on Fisher's exact test, for various underlying control
rates. The maximum width of (two-sided) 95% confidence intervals is also shown. For
continuous outcomes, such as mean RCR values, the detectable difference is presented as
the effect size (Wilcoxon rank-sum test); the width of a 95% confidence interval is also
shown. Based on our previous data (44), we expected the spontaneous positive outcome rate
in controls to be approximately 10%, and selected our group sizes accordingly, using N = 20
evaluable animals per dose/time/model group for Tier 1 (24-h outcomes).
Prior to formal statistical analysis of outcomes, potential data errors or outliers and
necessary variable transformations were examined. Standard descriptive statistics including
means, standard deviations and proportions were computed for all measures. Confidence
intervals (95%) were produced for all summary statistics. In Tier 2, exact versions of
nonparametric tests were to be used for k-group comparisons, including Wilcoxon and
Kruskal–Wallis tests for continuous measures and Fisher's exact or McNemar's tests for
proportions. Linear regression was also planned to evaluate associations among secondary
endpoints obtained in Tier 2. The dependent variables will be the primary endpoints from
Tier 1 (mitochondrial function and injury volume) and Tier 2 (cognition, balance,
actigraphy). Predictor variables will be the potential physio-markers (point-of-care metrics
such as microdialysis and serum biomarkers). It is recognized that the large number of
simultaneous experiments raises the possibility of inflation of type I error through these
future multiple comparisons. This would be carefully considered in the evaluation of all
results.
Tier 1 efficacy was defined as having ≥30% more of the N = 20 animals in a CsA dose/time/
model group with a combined positive outcome (based upon mitochondrial function and
neuropathology) compared with injured time/model controls receiving only saline (Agentspecific evaluation metrics for screening in Tier 1). The specific numbers and calculations
used to determine positive outcome rate in this study are designed to overcome the inherent
limitations of using small sample sizes to estimate the response of a population. Essentially,
because of the significant expense of large animal work, statistical approaches must be used
to determine true potential or underlying promise from a small number of subjects. In the
Results (Tier 1 positive outcome rates), we report that we have a fairly consistent
spontaneous “positive outcome” rate of 30%–35% in our vehicle control animals because
even after mild-to-moderate rapid head rotation or cortical impact, approximately one-third
of the animals have modest mitochondrial or pathological damage. Our effectiveness
evaluation dictates that for a dose to move on to Tier 2, a treated group must have an
underlying “positive outcome” rate of 60%–65%, respectively. Statistically, the larger the
group one samples, the more likely the group estimates the true or underlying response of a
population. For smaller groups, we must consider the errors associated with our uncertainty
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that the results reflect the true or underlying positive outcome rate of the injured animal
population.
If we fail to consider the response rate measurement uncertainty in our preclinical study with
20 animals in each of the four dose-time study arms, we would reject any dose that had less
than 13 animals (which is 65% of N = 20) “above the positive outcome bar” in each group.
However, because our measurement of a “positive outcome” rate is only an approximation
of the true population response with this small sample size, we would have a 40%
probability of excluding a dose with an inherent positive outcome rate that met our criteria
(40% beta error). This 40% probability of excluding a dose with an underlying response rate
that actually met our effectiveness evaluation criteria is a risk of rejecting a successful dose
that far exceeds the standard for screening for a promising agent in the pharmaceutical
industry (10). Instead, we set our beta error risk at the pharmaceutical industry standard for
single-arm randomized clinical trials (10), accepting a 5% chance of excluding a dose with
an inherent positive outcome rate that met our effectiveness evaluation criteria of moving a
dose forward if its underlying positive outcome rate ≥ 60%–65%. More details are provided
in Tier 1 positive outcome rates.
Tier 1 therapy development study design
Only injured animals were evaluated in Tier 1. Injured animals received either saline vehicle
(0 mg/kg) or CsA treatment at 1 of four different doses (10, 20, 40, 60 mg/kg) delivered
using a bolus followed by a continuous infusion for 24 h (five doses). Treatment was
initiated 1 h after injury or 6 h after injury (two timepoints) and extended for 24 h. Both
brain injury types were studied: RNR diffuse injury and CCI focal injury. Taken together, 5
doses × 2 timepoints × 2 injury models yields 20 groups. Each of these 20 dose-time-model
groups has two outcome measures evaluated (N = 10 animals for neuropathology and N =
10 for mitochondrial function). Because one of our central hypotheses was that mitigation of
mitochondrial dysfunction leads to improved neuropathology, our effectiveness evaluation
dictated that the success of a dose must be evaluated by combining treatment-associated
improvements in mitochondrial function and pathology (N = 20 per treated group). A second
central hypothesis is that the dose of CsA may depend on the delay to initiation of treatment
and the injury type. Thus, in our study design, analysis plan and effectiveness evaluation, the
five doses were clustered together into four single-arm randomized preclinical trials for
CsA, one for each of the four start time-model combinations. As mentioned earlier,
untreated injured controls were added in year 2. To reduce costs, we assumed untreated
injured controls were similar regardless of the delay to saline administration, and we
reduced the number of 6-h controls, as shown in Tables 2 and 3. Taken together, the final
Tier 1 planned enrollment was N = 440 injured piglets.
Piglets (N = 440 females, 4 weeks old) were anesthetized, instrumented and monitored as
described previously (44), and buprenorphine (0.02 mg/kg IM) was administered for
analgesia. An IV with low absorbance tubing was inserted into the cephalic vein, and
tunneled subcutaneously to the mid-scapula to an ambulatory infusion pump (3D BT mini
infusion, Strategic Applications Inc., Infusion Technologies, Lake Villa, IL, USA), to
administer CsA or saline, and to withdraw pre- and 24-h post-injury blood samples for
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serum protein biomarker analysis. Animals were assigned to receive CCI or RNR injury. As
mentioned earlier, for CCI, a skull-mounted, spring-loaded blunt indentation device was
used to deform approximately 1 cm3 of the cortical rostral gyrus rapidly (4 ms), with a
typical lesion volume (Vinj) of 8% of the hemisphere or 4% of the cerebrum (20). For RNR,
the snout was secured, and the head rotated 60–70° rapidly (12–20 ms) in the sagittal plane
without impact (68). Within each injury group, animals were assigned to a CsA post-TBI
start time of 1 or 6 h, and randomized to one of the four CsA dose groups (10, 20, 40, 60
mg/kg/day) or saline. Treatment was administered intravenously according to the dosing
schedule described above. Post-injury, animals were monitored until fully recovered from
anesthesia and observed until they demonstrated vocalization (without squealing), steady
ambulation, no aggression or avoidance behavior, no piloerection and presence of proper
feeding, and then returned to the animal housing unit after the initial IV loading dose, with
continuation of the infusion delivered in the housing facility. Typically, during recovery,
animals initially exhibited purposeless behavior, had poorly coordinated motor function and
were unusually lethargic or easily agitated, similar to mild-to-moderate TBI in the child.
After 24 h of CsA treatment, animals were anesthetized, and a final blood sample was
obtained. Subjects were sacrificed, and either fresh brain tissue was collected to determine
the mitochondrial function (N = 10 per group), or brains were perfused transcardially with
unbuffered formalin to quantify injury volume (Vinj) via histology (N = 10 per group).
For mitochondrial isolation, the brain was exposed, and specimens were removed rapidly
after euthanasia. From RNR animals, bilateral 3–5 mL regions of cortex and hippocampus
were removed. From CCI animals, a 2-cm-per-side cube of cortex and underlying white
matter centered at the CCI impact site was removed and necrotic tissue was removed, and a
mirrored sample from the contralateral side was resected. From the fresh tissue in year 1 of
Tier 1, mitochondria were isolated rapidly (88), and RCR (RCR = State 3 divided by State
4) was determined (72). In year 2, the same regions were homogenized and a serial
substrate, uncoupler, inhibitor titration (SUIT) protocol previously used for rodent brain
tissue (43) was optimized for the piglet, and maximal coupled phosphorylating respiration
capacity via convergent input through complexes I and II (OXPHOSCI + CII) was determined
and normalized by LEAK respiration or State 40.
For histology, after perfusion, brains were removed and immersed in fixative. Brains were
cut in serial 3-mm coronal sections, photographed for determining total cerebral volume,
and examined for gross pathology to document subdural and subarachnoid hemorrhages and
surface contusions. Finally, 6-μm-thick slices from each 3 -mm coronal section were stained
with hematoxylin and eosin (H&E) and β-APP, and examined by the neuropathologist on
our team (CS, blinded to experimental group) who reviewed every field of every slide
microscopically. Documented major pathology includes hemorrhages, established infarcts
(changes in staining intensity) and ischemic neurons (cell shrinkage and eosinophilia).
Axonal injury was detected via β-APP immunohistochemistry to identify disruption of
axonal flow and regions of ischemic axonal injury. The distribution of axonal and neuronal
injury was annotated on the digital photographs for each animal (31, 96). To quantify the
extent of brain injury, the brain periphery of every 3-mm section was traced to determine the
brain area (Photoshop, Adobe Systems Incorporated, San Jose, CA, USA). The locations of
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white matter damage, infarct and ischemia were traced in each slice using the same
procedure to determine injured brain area. Lesion volume (Vinj) was defined as total injured
area (axonal injury plus infarct/ischemic lesions) divided by total slice area.
Tier 2 study design
Tier 2 was designed to mimic the clinical care setting, and prospective criteria for
effectiveness have been identified, but studies have not been conducted to date. In Tier 2, we
plan to evaluate 6-day post-TBI neurofunctional outcome metrics for up to two doses for
each model/time group meeting our effectiveness criteria for Tier 1. The results of treated
injured animals will be compared with injured piglets administered vehicle (N = 30/group),
in naïve shams (N = 12), and CCI and RNR uninjured shams with an intensive care unit
(ICU) experience (N = 12/group). The most effective CsA treatment-model combinations
will then be tested in males to assess for any gender effects and serum processed for CsA
concentrations to translate porcine PK to humans using a computational model. Focal and
diffuse injuries will be created as in Tier 1. As in Tier 1, treatment will be an IV load
followed by continuous infusion, with treatment duration of 24 h. Saline-only treatment of
injured animals will be initiated 1 h post-injury. During the first 24 h after injury or sham
anesthesia, animals will receive continuous neurointensive care monitoring, including CBF,
intracranial pressure (ICP), mean arterial pressure (MAP) and PbtO2, as well as IV fluids
and respiratory support. We will use a clinical-based protocol to ensure consistent cerebral
perfusion pressure (CPP) and ICP management (9) (see flowchart provided in Figure 2).
During this 24-h period, serial blood and microdialysis samples will be obtained to measure
PK, biomarkers and lactate/pyruvate ratio (LPR) time courses. The biomarkers and LPR are
unconfirmed intensive care measures that will be used in a secondary analysis to guide
clinical trial design. These serum, microdialysis and physiological biomarkers are not
included in the effectiveness criteria; rather, they will be evaluated as informative prognostic
markers of injury severity and recovery.
After the injury has been completed and an unconsciousness time was recorded (reaction
time post-injury to an interdigital toe pinch), anesthesia will be switched to a continuous
midazolam (0.1–0.6 mg/kg/h) and fentanyl (50 μg/kg/h) IV infusion for 24 h (Day 0–1)
while being monitored in the NIH-funded state-of-theart Neurointensive Care and
Assessment Facility that houses pigs for up to 3 days after TBI with round-the-clock care.
Cerebral microdialysis probe (CMA 12 PAS elite 4 mm probes, CMA, Torshamnsgatan,
Sweden), a thermal diffusion CBF probe (Bowman Perfusion Monitor, Hemedex
Cambridge, MA, USA) and a brain tissue oxygenation electrode with temperature probe
(Licox, Integra Plainsboro Township, NJ, USA) will be inserted into the frontal lobes of the
RNR model. In the CCI model, probes will be placed in the ipsilateral frontal lobe. A fiberoptic ICP monitor (Camino, Integra) will also be placed in the frontal lobe. Mean arterial
blood pressure will be monitored via a cuff on the forelimb. Cerebral microdialysis samples
will be collected at 1, 2, 4, 6, 12, 18 and 24 h post-injury at a flow rate of 10 μL/minute
using 0.9% NaCl as the dialysate. Immediately after collection, samples will be stored at
−70°C. Levels of lactate and pyruvate will be measured in the dialysate using a
microdialysis analyzer (ISCUS-flex, M Dialysis, Stockholm, Sweden). Lactate-pyruvate
ratios will be calculated from their respective values.
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During the 24-h ICU period, piglets will receive continuous neurointensive care monitoring
(CBF, ICP, MAP, brain tissue oxygenation content), intravenous fluids and respiratory
support (if necessary), and isotonic intravenous fluids to maintain normovolemia and
normoglycemia and/or vasopressors to support a CPP ≥40 mmHg and ICP ≤ 20 mmHg, to
ensure consistent management across groups, and to provide fidelity between current firsttier clinical practice for acute management of severe TBI in pediatrics (3, 4, 41) and our
translational platform (see flowchart). All animals that required mechanical ventilation will
have minute ventilation adjusted to maintain PaCO2 between 35 and 45 mmHg and oxygen
titrated to avoid hypoxia (5, 12). While intubated, piglets will receive midazolam (0.6
mg/kg/h) and fentanyl (25–100 mcg/kg/h) infusions for sedation and analgesia, respectively,
the most common sedation regimen used in human pediatric critical care. Because of the
indwelling cerebral monitors, all piglets will receive antibiotics (cefazolin, 25 mg/kg, every
8 h) during the 24-h stay in the ICU.
During this 24-h ICU period, 12 serial blood samples will be removed for CsA concentration
determination from some of the animals (N = 16/group) in each injured study group using
low absorbance tubing and syringes. Specifically, eight pigs from each group will undergo
the following 12-sample PK sampling strategy: pre loading dose, immediately post loading
dose, and then 0.5, 1.5, 2.5, 4, 6, 9, 13, 17 and 21 h after the start of the infusion and
immediately prior to end of infusion. Eight pigs from each group will undergo the following
complementary 12-sample PK sampling strategy: pre loading dose, immediately post
loading dose, and then 0.5, 1.5, 2, 3, 5, 7, 11, 15 and 19 h after the start of the infusion and
immediately prior to end of infusion. Serial blood samples will be obtained from the others
(N = 12/group) and all uninjured groups to measure biomarkers at four timepoints: preinjury, and at 8 and 24 h, and 6 days post-injury. The PK and pharmacodynamic data will be
used to determine optimal porcine CsA exposure, and we will determine if LPR and
biomarker samples correlate with cognitive outcomes in a secondary analysis.
After 24 h, animals will be weaned from support. The same recovery practice used for our
24-h survival studies (in Tier 1) will be implemented for the recovery process of this group.
The animals will be returned to the animal care unit when the following criteria for
stabilization are met: vocalization without squealing, steady ambulation, no aggression or
avoidance behavior, no piloerection, and presence of proper feeding/drinking. The animals
will be allowed to recover for the remainder of the day (Day 1). Any animal not meeting
these criteria by the end of Day 1 will be sacrificed and excluded from analysis. Upon
successful recovery, the animals will continue on to participate in post-injury neurofunctional studies on Days 1–6 post-TBI, as described previously (40, 89, 90).
To demonstrate neurofunctional efficacy, neurofunctional assessments will be performed for
6 days post-injury. To move forward to consideration for clinical trial, a dose must have a
statistically significant improvement in at least one neurofunctional metric compared with
the similarly injured group receiving vehicle. Only fully evaluable treated and vehicleadministered subjects from the RNR and CCI injuries (30/group) will be considered, and
performance metrics may vary by the injury model, because we find that the distribution of
brain injury affects functional outcomes (40). If an effective dose for at least one injury type
(diffuse RNR or focal CCI) with significant neurofunctional improvement post-injury in
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female piglets is identified, that dose will be evaluated for one injury model in male piglets
to identify any sex-related therapeutic differences.
Record keeping methods
To facilitate translation from preclinical studies to investigational new drug application
submission for a future clinical trial, we developed drug accountability reporting forms and
a patient record system to provide easy translation to human trials. In addition, all data entry
forms are in a secure “cloud”-based application (REDCap system, Research Electronic Data
Capture) to facilitate the multisite data entry (University of Pennsylvania, Massachusetts
General Hospital and Edinburgh University), with appropriate backup and user edit logging
time stamps. Furthermore, for each of the four groups defined by injury model (RNR or
CCI) and time (1 or 6 h post-injury), and each of the outcomes (RCR or pathology), a
separate randomization schedule was created prospectively. Each schedule used a permuted
block design with block sizes of six for the 1-h experiments (which included 10 vehicle
controls) and block sizes of five for the 6-h experiments (five vehicle controls). Allowances
were made for the replacement of animals that did not complete the experiment and
additional controls in year 2. The schedules were created in Excel (Microsoft Corportion,
Redmond, WA, USA) and then locked to electronic editing. These rigorous documentation
instruments are essential for ease of translation to clinical trials.

RESULTS
For Tier 1, we studied 497 piglets (Table 2) to achieve the target enrollment of 440 injured
subjects in our preclinical trial. We excluded 57 subjects based upon our prospectively
defined inclusion/exclusion criteria, including difficulties intubating or placing lines prior to
injury, prolonged desaturation (>5 minutes at <90% oxygen while breathing room air) after
injury, failure to maintain normothermia (between 37 and 39°C), failure to reach milestones
for return of spontaneous breathing and return to the husbandry unit by 5 h post-TBI, and
amount of agent dispensed from the infusion pump by sacrifice is >15% less than expected.
Specifically, animals were excluded secondary to technical issues with the intravenous drug
delivery system (N = 28), failure to achieve post-injury recovery benchmarks for return to
the husbandry unit (N = 21), and various technical problems pre- or post-injury that
precluded adherence to the protocol (N = 8).
Tier 1 positive outcome rates
Each of the four start time-model combinations was evaluated as a separate single-arm
randomized preclinical trial for CsA efficacy. To determine the total positive outcome rate
for each dose-time-model combination, the numbers of pathology and mitochondrial
function positive outcomes (as defined in Pathology threshold for positive outcome and
Mitochondrial threshold for positive outcome) from the N = 20 animals studied were added
together. The injured vehicle control “spontaneous” total positive outcome rate was highly
consistent (30%–35%) across all model-time combinations, indicating that about one-third
of untreated animals fall above the threshold, similar to the variability in outcomes expected
for animal models of mild-to-moderate TBI. Based on our Statistical Considerations, our
prospective effectiveness evaluation criteria (Agent-specific evaluation metrics for screening
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in Tier 1) dictated that we designate as candidates all CsA doses with a likelihood of having
an underlying total positive outcome rate that is 30% more than the injured untreated vehicle
rate (30%–35%) for that model-time “trial,” or a 60%–65% total positive outcome rate.
Given our sample size and imposing the pharmaceutical industry standard for false-positive
and false-negative rates in a traditional single-arm randomized clinical trial (10), this
strategy serves to identify the required number of positive outcomes any dose must achieve
to be considered as a candidate. The beta error accepted by the industry (<5%) ensures that
we have a >95% chance of identifying all doses with an underlying positive outcome rate
required by our 60%–65% Evaluation Plan threshold for effectiveness (Agent-specific
evaluation metrics for screening in Tier 1).
All positive outcome rates are provided in Table 3. Specifically, using the pharmaceutical
industry standard for single-arm randomized clinical trials (10) where beta error is 5%, for
Tier 1 group sizes of 20 we accepted any dose with at least 10 positive outcome responses
(50% experimental positive outcome rate) as being consistent with the likelihood of having
an underlying rate of at least 65%. For the one model/time combination with a vehicle
control positive outcome rate of 30%, our effectiveness evaluation targets an underlying rate
of 60% as an effective dose to continue on to Tier 2, and we accept any dose with nine
positive outcomes (45% experimental response rate) as being consistent with the likelihood
of having an underlying rate of at least 60%.
No CsA doses in the RNR model with 1-h post-TBI delay start time were effective. One
dose (20 mg/kg) in the RNR 6-h delay start time group and one dose (60 mg/kg) in the CCI
1-h delay group met our criteria for effectiveness. Three doses (10, 20 and 60 mg/kg) met
our criteria in the CCI 6-h delay group (shaded in yellow in Table 3). The same data are
presented in a graphical format for the four dose-time study arms in Figure 3, with the
colored vertical bars indicating total positive outcome rates for each dose, the dark
horizontal line indicating the underlying effectiveness evaluation positive outcome rate
threshold, the gray zone as the 5% beta error, and the bright yellow line as the positive
outcome rate threshold that must be met to achieve our effectiveness evaluation targets with
our small sample size and a 5% beta error. All doses at or exceeding the yellow line in
Figure 3 meet the underlying positive outcome rate prescribed by our effectiveness
evaluation plan (Agent-specific evaluation metrics for screening in Tier 1) and are defined
as “successful” doses. As can be seen, several doses and administration start times met
criteria for being promising and going on to Tier 2 testing for each injury model. Not
surprisingly, given the convex parabolic pharmacodynamics for CsA demonstrated in rodent
TBI treatment trials (85, 87), we often observed a narrow optimal dose range, and we did not
observe that a linearly increasing concentration of CsA had increasingly positive therapeutic
value.
Tier 1 dose response
Although this study was underpowered to identify dose-responses in Tier 1, we examined
qualitative trends in dose effectiveness in either pathology or mitochondrial function in each
injury type. First, we consider trends in dose effectiveness for each injury type, followed by
those for each delay to initiation of treatment. Raw data of the injury volume (as a percent of
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total brain volume) (top row, Figure 4) and mitochondrial function (bottom row) are
provided (mean ± SE). Arrows indicate which direction is associated with improved
outcomes. As in humans, the injury presents with a high degree of variability, even given the
same mechanical input (head rotational velocity in RNR and cortical deformation in CCI) as
demonstrated by standard error bars in the vehicle no-treatment groups (blue bars) for
injured volume (top row) and mitochondrial function (bottom row).
After RNR injury, the 20 mg/kg dose (green bars, Figure 4) meets the total “positive
outcome” effectiveness evaluation rate threshold in the 6-h delay to treatment group by
improving both pathology and mitochondrial function. The 60 mg/kg dose (orange) in the 6h delay group looks promising but falls below the total positive outcome rate effectiveness
evaluation threshold because of larger variability in the mitochondrial response at that dose.
After CCI injury, increases in the “positive outcome” response rate with treatment tend to be
driven by improvements in lesion volume pathology at higher CsA doses rather than doserelated improvement in mitochondrial function in the severely compromised penumbral
region of the cortical lesion.
Given the variability in outcomes in large animal models, it is not surprising to us that the
qualitative therapy effect sizes appear relatively small in a large animal, limited-subjectnumber trial design. Given that we can only examine trends because our study is
underpowered to examine dose effect sizes, our data obtained in a rigorous study, with two
injury models representing the focal and diffuse extremes along the spectrum of TBI,
support our hypothesis that the underlying therapeutic mechanism and most effective CsA
dose may vary with injury type, as in pheno- and geno-specific cancer therapies.

DISCUSSION
Our effectiveness evaluation criteria are ambitious: to identify CsA doses that demonstrate
clearly demonstrable protection levels for the developing brain. For each start time and
model combination, our goal was to identify all effective doses and select two doses to move
forward to Tier 2: the minimum effective dose and the dose with the greatest magnitude of
neuroprotection. If no doses for a time-model combination demonstrate effectiveness, that
time-model combination would be designated as futile and discontinued from further study.
Using this strategy, we found that one efficacious CsA dose qualified to move forward to
further study in Tier 2 in each of three model-start time trials. Specifically, we find that no
CsA doses in the RNR model with 1-h post-TBI delay start time were effective. One dose
(20 mg/kg) in the RNR 6-h delay start time group and one dose (60 mg/kg) in the CCI 1-h
delay group met our criteria and are worthy of study in Tier 2. Three doses (10, 20 and 60
mg/kg) met our criteria in the CCI 6-h delay group. Consistent with our effectiveness
evaluation plan, because the lowest dose also had the highest rate of positive outcomes, only
that dose (10 mg/kg) would move forward for study of long-term neurofunctional outcomes.
It is interesting to note that lower doses were more effective at longer delays to treatment (6
h) and higher doses were more effective with more acute (1 h) post-TBI administration.
Consistent with other investigators who have reported a parabolic pharmacodynamics in
rodent models of TBI (85, 87), we identified a narrow optimal dose range. What has been of
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additional interest is that the results suggest that this agent may work differently in the
different injury types, paving the way for injury-type-specific neuroprotective strategies.
As we hypothesized, we speculate that these findings may have implications for temporal
specificity of therapeutic mechanistic targets. To inform our human trial design, we included
two clinically relevant treatment windows (1 and 6-h delays to the initiation of 24-h
treatment) and found that there are promising doses at both timepoints. We conclude that
CsA has a practical, generous and promising therapeutic window. Future studies should
investigate further why some doses were effective at 6 h and not 1 h post-TBI because this
finding could significantly alter some of the usual assumptions about optimal timing of
treatment of TBI.
Future preclinical animal studies should investigate the interesting underlying mechanisms
associated with injury-specific responses, the role of treatment duration on outcome and a
more precise dose–response curve. These studies are outside the scope of this restricted
experimental design and our limited funding mechanism, and would require larger group
sizes to detect the more subtle changes in outcome that occur with different injury
mechanisms and CsA doses. It should be noted that the variability in even the most carefully
standardized large animal models almost certainly will limit the effect sizes seen, and this
may be a clearer reflection of what would likely occur in a human neuroprotection trial.
This is the first report of a preclinical trial paradigm to evaluate therapeutic effectiveness of
any TBI treatment in both isolated focal and diffuse injuries, and our findings show that
therapeutic dose level and response mechanisms vary with TBI type. These Tier 1 results
support CsA as a potentially promising therapy for both focal and diffuse injuries in the
immature brain that warrants further investigation to evaluate neurofunctional effectiveness.
With funding for Tier 2 in this translational model, long-term neurofunctional outcomes
would be evaluated after a clinically fidelic ICU experience for the promising CsA doses
and would include naïve controls for behavior norms, uninjured anesthetized controls who
undergo an ICU experience (with potential cognitive and behavioral impact), an injured CCI
vehicle group and an injured RNR vehicle control group (total of seven groups, 30/group).
In conclusion, this project is the first immature large animal translational treatment trial for
pharmacologic intervention for TBI in children. Its overall structure and milestones were
designed specifically to parallel those used in human intervention trials in the pediatric age
group. Because TBI is heterogeneous, the trial tests the intervention in two different injury
types that bracket the range seen in clinical injury and uses two different times of drug
administration and four different doses of drug. We designed our immature large animal
model platform as a rigorous preclinical screen for a TBI intervention that overcomes some
of the failures attributed to previous rodent trials (45) and specifically included a
randomized blinded experimental design, careful attention to statistical considerations, data
handling, clinically relevant conditions and efficacy testing in both diffuse and focal TBI.
We conclude that our platform, while arduous and detailed, has proven itself as a successful
comprehensive preclinical screen to identify potential treatments for use in patients with
TBI.

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 19

ACKNOWLEDGMENTS
The preclinical study was supported by the NIH grant U01NS069545. We thank our NIH partners Drs Ramona
Hicks and Linda McGavern for their insightful questions that shaped our study design and their long-standing
support for the project. We are grateful for the expert technical assistance, many long hours of participation and
deep dedication to the project by Courtney Robertson, Athena Zuppa, Jill Ralston, Ashley Bebee, Kortne Hudick,
Sabrina Taylor, Christopher Seufert, Carter Dodge, Marissa Fiorello and Jamie Rose. We appreciate the long,
tedious hours contributed by Erica Hummel, Jesi Kim, Peter Chhour, Susie Cha and Rachel Margulies digitizing
photographs of injured brain sections to determine lesion volume pathology values.

REFERENCES
1. Adams JH, Graham DI, Gennarelli TA. Head injury in man and experimental animals:
neuropathology. Acta Neurochir Suppl (Wien). 1983; 32:15–30. [PubMed: 6581702]
2. Adams JH, Graham DI, Murray LS, Scott G. Diffuse axonal injury due to nonmissile head injury in
humans: an analysis of 45 cases. Ann Neurol. 1982; 12:557–563. [PubMed: 7159059]
3. Adelson PD, Bratton SL, Carney NA, Chesnut RM, du Coudray HE, Goldstein B, et al. Guidelines
for the acute medical management of severe traumatic brain injury in infants, children, and
adolescents. Chapter 1: introduction. Pediatr Crit Care Med. 2003; 4(Suppl. 3):S2–S4. [PubMed:
12847337]
4. Adelson PD, Bratton SL, Carney NA, Chesnut RM, du Coudray HE, Goldstein B, et al. Guidelines
for the acute medical management of severe traumatic brain injury in infants, children, and
adolescents. Chapter 17. Critical pathway for the treatment of established intracranial hypertension
in pediatric traumatic brain injury. Pediatr Crit Care Med. 2003; 4(Suppl. 3):S65–S67. [PubMed:
12847353]
5. Adelson PD, Clyde B, Kochanek PM, Wisniewski SR, Marion DW, Yonas H. Cerebrovascular
response in infants and young children following severe traumatic brain injury: a preliminary report.
Pediatr Neurosurg. 1997; 26:200–207. [PubMed: 9436831]
6. Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock MR. Cyclosporin A improves
brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion
injury in rats. J Neurotrauma. 2002; 19:829–841. [PubMed: 12184853]
7. Armstead W, Kurth C. Different cerebral hemodynamic responses following fluid percussion brain
injury in the newborn and juvenile pig. J Neurotrauma. 1994; 11:487–497. [PubMed: 7861442]
8. Bates TE, Almeida A, Heales SJ, Clark JB. Postnatal development of the complexes of the electron
transport chain in isolated rat brain mitochondria. Dev Neurosci. 1994; 16:321–327. [PubMed:
7768212]
9. Brain Trauma Foundation. Guidelines for the management of severe head injury. J Neurotrauma.
2007; 24(Suppl. 1):S1–S106.
10. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol. 2009; 27:3073–3076.
[PubMed: 19451415]
11. Casey PA, McKenna MC, Fiskum G, Saraswati M, Robertson CL. Early and sustained alterations
in cerebral metabolism after traumatic brain injury in immature rats. J Neurotrauma. 2008;
25:603–614. [PubMed: 18454682]
12. Chesnut RM, Marshall LF, Klauber MR, Blunt BA, Baldwin N, Eisenberg HM, et al. The role of
secondary brain injury in determining outcome from severe head injury. Journal of Trauma. 1993;
34:216–222. [PubMed: 8459458]
13. Cibulskyte D, Pedersen M, Jakobsen P, Hansen HE, Mortensen J. Pharmacokinetic
characterization of a pig model of ciclosporin A nephrotoxicity following intravenous
administration. Pharmacol Res. 2007; 56:311–317. [PubMed: 17870611]
14. Doppenberg EM, Choi SC, Bullock R. Clinical trials in traumatic brain injury: lessons for the
future. Journal of Neurosurgical Anesthesiology. 2004; 16:87–94. [PubMed: 14676577]
15. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014; 505:612–613.
[PubMed: 24482835]
16. Del Maestro R, McDonald W. Distribution of superoxide dismutase, glutathione peroxidase and
catalase in developing rat brain. Mech Ageing Dev. 1987; 41:29–38. [PubMed: 3431167]

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 20

17. Duhaime AC. Large animal models of traumatic injury to the immature brain. Dev Neurosci. 2006;
28:380–387. [PubMed: 16943661]
18. Duhaime AC, Hunter JV, Grate LL, Kim A, Demidenko E, Golden JA, Harris C. Magnetic
resonance imaging studies of age-dependent responses to scaled focal brain injury in the piglet. J
Neurosurg. 2003; 99:542–548. [PubMed: 12959443]
19. Duhaime AC, Hunter JV, Grate LL, Kim A, Golden J, Demidenko E, Harris C. Magnetic
resonance imaging studies of age-dependent responses to scaled focal brain injury in the piglet. J
Neurosurg. 2003; 99:542–548. [PubMed: 12959443]
20. Duhaime AC, Margulies SS, Durham SR, O'Rourke MM, Golden JA, Marwaha S, Raghupathi R.
Maturation-dependent response of the piglet brain to scaled cortical impact. J Neurosurg. 2000;
93:455–462. [PubMed: 10969944]
21. Duhaime AC, Saykin AJ, McDonald BC, Dodge CP, Eskey CJ, Darcey TM, et al. Functional
magnetic resonance imaging of the primary somatosensory cortex in piglets. J Neurosurg. 2006;
104(Suppl. 4):259–264. [PubMed: 16619637]
22. Durham SR, Duhaime AC. Maturation-dependent response of the immature brain to experimental
subdural hematoma. J Neurotrauma. 2007; 24:5–14. [PubMed: 17263666]
23. Durham SR, Raghupathi R, Helfaer MA, Marwaha S, Duhaime AC. Age-related differences in
acute physiologic response to focal traumatic brain injury in piglets. Pediatr Neurosurg. 2000;
33:76–82. [PubMed: 11070433]
24. Eucker SA, Smith C, Ralston J, Friess S, Margulies SS. Physiological and histopathological
responses following closed rotational head injury depend on direction of head motion.
Experimental Neurology. 2011; 227(1):79–88. [PubMed: 20875409]
25. Ferrand-Drake M, Zhu C, Gido G, Hansen AJ, Karlsson JO, Bahr BA, et al. Cyclosporin A
prevents calpain activation despite increased intracellular calcium concentrations, as well as
translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons
exposed to transient hypoglycemia. J Neurochem. 2003; 85:1431–1442. [PubMed: 12787063]
26. Finn WF, McCormack AJ, Sullivan BA, Hak LJ, Clark RL. Influence of the rate of infusion on
cyclosporine nephrotoxicity in the rat. Ren Fail. 1989; 11:3–15. [PubMed: 2772285]
27. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH. Update of the stroke
therapy academic industry roundtable preclinical recommendations. Stroke. 2009; 40(6):2244–
2250. [PubMed: 19246690]
28. Folbergrova J, Li PA, Uchino H, Smith ML, Siesjo BK. Changes in the bioenergetic state of rat
hippocampus during 2.5 min of ischemia, and prevention of cell damage by cyclosporin A in
hyperglycemic subjects. Exp Brain Res. 1997; 114:44–50. [PubMed: 9125450]
29. Friess SH, Ichord RN, Owens K, Ralston J, Rizol R, Overall KL, et al. Neurobehavioral functional
deficits following closed head injury in the neonatal pig. Exp Neurol. 2007; 204:234–243.
[PubMed: 17174304]
30. Fukui S, Signoretti S, Dunbar JG, Marmarou A. The effect of cyclosporin A on brain edema
formation following experimental cortical contusion. Acta Neurochir Suppl. 2003; 86:301–303.
[PubMed: 14753457]
31. Gentleman SM, Roberts GW, Gennarelli TA, Maxwell WL, Adams JH, Kerr S, Graham DI.
Axonal injury: a universal consequence of fatal closed head injury? Acta Neuropathol (Berl).
1995; 89:537–543. [PubMed: 7676809]
32. Ghafari A, Makhdoomi K, Ahmadpour P, Afshari AT, Fallah MM, Rad PS. Low-dose versus highdose cyclosporine induction protocols in renal transplantation. Transplant Proc. 2007; 39:1219–
1222. [PubMed: 17524937]
33. Gnaiger E. Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of
mitochondrial physiology. Int J Biochem Cell Biol. 2009; 41:1837–1845. [PubMed: 19467914]
34. Graham D, Ford I, Adams J, Doyle D, Lawrence A, McLellan D. Fatal head injury in children. J
Clin Pathol. 1989; 42:18–22. [PubMed: 2921340]
35. Graham DI, McIntosh TK, Maxwell WL, Nicoll JA. Recent advances in neurotrauma. J
Neuropathol Exp Neurol. 2000; 59:641–651. [PubMed: 10952055]
36. Hall ED, Traystman RJ. Role of animal studies in the design of clinical trials. Front Neurol
Neurosci. 2009; 25:10–33. [PubMed: 19478492]

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 21

37. Hansson MJ, Persson T, Friberg H, Keep MF, Rees A, Wieloch T, Elmer E. Powerful cyclosporin
inhibition of calcium-induced permeability transition in brain mitochondria. Brain Res. 2003;
960:99–111. [PubMed: 12505662]
38. Hoyert DL, Heron MP, Murphy SL, Kung HC. Deaths: final data for 2003. Natl Vital Stat Rep.
2006; 54:1–120. [PubMed: 16689256]
39. Hutchison JS, Ward RE, Lacroix J, Hebert PC, Barnes MA, Bohn DJ, et al. Hypothermia therapy
after traumatic brain injury in children. N Engl J Med. 2008; 358:2447–2456. [PubMed:
18525042]
40. Jaber S, Sullivan S, Margulies SS. Noninvasive metrics for identification of brain injury deficits in
piglets. Dev Neuropsychol. 2015; 40(1):34–39. [PubMed: 25649778]
41. Jankowitz BT, Adelson PD. Pediatric traumatic brain injury: past, present and future. Dev
Neurosci. 2006; 28:264–275. [PubMed: 16943650]
42. Josan VA, Sgouros S. Early decompressive craniectomy may be effective in the treatment of
refractory intracranial hypertension after traumatic brain injury. Childs Nerv Syst. 2006; 22:1268–
1274. [PubMed: 16496158]
43. Karlsson M, Hempel C, Sjovall F, Hansson MJ, Kurtzhals JA, Elmer E. Brain mitochondrial
function in a murine model of cerebral malaria and the therapeutic effects of rhEPO. Int J Biochem
Cell Biol. 2013; 45:151–155. [PubMed: 22903021]
44. Kilbaugh TJ, Bhandare S, Lorom DH, Saraswati M, Robertson CL, Margulies SS. Cyclosporin A
preserves mitochondrial function after traumatic brain injury in the immature rat and piglet. J
Neurotrauma. 2011; 28:763–774. [PubMed: 21250918]
45. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for
transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;
490:187–191. [PubMed: 23060188]
46. Levin HS, Mendelsohn D, Lilly MA, Yeakley J, Song J, Scheibel RS, et al. Magnetic resonance
imaging in relation to functional outcome of pediatric closed head injury: a test of the OmmayaGennarelli model. Neurosurgery. 1997; 40:432–440. [PubMed: 9055281]
47. Li PA, Kristian T, He QP, Siesjo BK. Cyclosporin A enhances survival, ameliorates brain damage,
and prevents secondary mitochondrial dysfunction after a 30-minute period of transient cerebral
ischemia. Exp Neurol. 2000; 165:153–163. [PubMed: 10964494]
48. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.
Nature. 2006; 443:787–795. [PubMed: 17051205]
49. Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI. Effect of high-dose cyclosporine on
etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug
resistance. Cancer Chemother Pharmacol. 2000; 45:305–311. [PubMed: 10755319]
50. Margulies S, Hicks R, Leaders CTfTW. Combination Therapies for Traumatic Brain InjuryProspective Considerations. J Neurotrauma. 2009; 26(6):925–939. [PubMed: 19331514]
51. Margulies S, Thibault L, Gennarelli T. Physical model simulations of brain injury in the primate. J
Biomech. 1990; 23:823–836. [PubMed: 2384494]
52. Marklund N, Bakshi A, Castelbuono DJ, Conte V, McIntosh TK. Evaluation of pharmacological
treatment strategies in traumatic brain injury. Curr Pharm Des. 2006; 12:1645–1680. [PubMed:
16729876]
53. Mazzeo AT, Alves OL, Gilman CB, Hayes RL, Tolias C, Niki Kunene K, Ross Bullock M. Brain
metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a
microdialysis study. Acta Neurochir (Wien). 2008; 150:1019–1031. discussion 31. [PubMed:
18781275]
54. Mazzeo AT, Brophy GM, Gilman CB, Alves OL, Robles JR, Hayes RL, et al. Safety and
tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective
randomized trial. J Neurotrauma. 2009; 26:2195–2206. [PubMed: 19621985]
55. Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective effects of
cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic
brain injury. J Cereb Blood Flow Metab. 2009; 29:87–97. [PubMed: 18714331]

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 22

56. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, et al. Very early
administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014; 371:2457–
2466. [PubMed: 25493974]
57. Missios S, Harris BT, Dodge CP, Simoni MK, Costine BA, Lee YL, et al. Scaled cortical impact in
immature swine: effect of age and gender on lesion volume. J Neurotrauma. 2009; 26:1943–1951.
[PubMed: 19469691]
58. Moppett IK. Traumatic brain injury: assessment, resuscitation and early management. Br J
Anaesth. 2007; 99(1):18–31. [PubMed: 17545555]
59. Morrison B 3rd, Saatman KE, Meaney DF, McIntosh TK. In vitro central nervous system models
of mechanically induced trauma: a review. J Neurotrauma. 1998; 15:911–928. [PubMed: 9840765]
60. Narayan RK, Michel ME, Ansell B, Baethmann A, Biegon A, Bracken MB, et al. Clinical trials in
head injury. J Neurotrauma. 2002; 19:503–557. [PubMed: 12042091]
61. Patrick PD, Blackman JA, Mabry JL, Buck ML, Gurka MJ, Conaway MR. Dopamine agonist
therapy in low-response children following traumatic brain injury. J Child Neurol. 2006; 21:879–
885. [PubMed: 17005105]
62. Pecinova A, Drahota Z, Nuskova H, Pecina P, Houstek J. Evaluation of basic mitochondrial
functions using rat tissue homogenates. Mitochondrion. 2011; 11:722–728. [PubMed: 21664301]
63. Picard M, Taivassalo T, Gouspillou G, Hepple RT. Mitochondria: isolation, structure and function.
J Physiol. 2011; 589(Pt 18):4413–4421. [PubMed: 21708903]
64. Picard M, Taivassalo T, Ritchie D, Wright KJ, Thomas MM, Romestaing C, Hepple RT.
Mitochondrial structure and function are disrupted by standard isolation methods. PLoS ONE.
2011; 6:e18317. [PubMed: 21512578]
65. Povlishock JT, Katz DI. Update of neuropathology and neurological recovery after traumatic brain
injury. J Head Trauma Rehabil. 2005; 20:76–94. [PubMed: 15668572]
66. Prabhakaran P, Reddy AT, Oakes WJ, King WD, Winkler MK, Givens TG. A pilot trial comparing
cerebral perfusion pressure-targeted therapy to intracranial pressure-targeted therapy in children
with severe traumatic brain injury. J Neurosurg. 2004; 100(5 Suppl. Pediatrics):454–459.
[PubMed: 15287454]
67. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathology. 2004;
14:215–222. [PubMed: 15193035]
68. Raghupathi R, Margulies SS. Traumatic axonal injury after closed head injury in the neonatal pig. J
Neurotrauma. 2002; 19:843–853. [PubMed: 12184854]
69. Raghupathi R, Mehr M, Helfaer M, Margulies S. Traumatic axonal injury is exacerbated following
repetitive close head injury in the neonatal pig. J Neurotrauma. 2004; 21:307–316. [PubMed:
15115605]
70. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited.
FASEB J. 2008; 22:659–661. [PubMed: 17942826]
71. Roberts I, Schierhout G, Alderson P. Absence of evidence for the effectiveness of five
interventions routinely used in the intensive care management of severe head injury: a systematic
review [see comments]. J Neurol Neurosurg Psychiatry. 1998; 65:729–733. [PubMed: 9810947]
72. Robertson CL, Saraswati M, Fiskum G. Mitochondrial dysfunction early after traumatic brain
injury in immature rats. J Neurochem. 2007; 101:1248–1257. [PubMed: 17403141]
73. Robertson CL, Soane L, Siegel ZT, Fiskum G. The potential role of mitochondria in pediatric
traumatic brain injury. Dev Neurosci. 2006; 28:432–446. [PubMed: 16943666]
74. Saatman KE, Duhaime A-C, Bullock R, Maas AIR, Valadka A, Manley GT, et al. Classification of
traumatic brain injury for targeted therapies. J Neurotrauma. 2008; 25(July):719–738. [PubMed:
18627252]
75. Saito A, Maier CM, Narasimhan P, Nishi T, Song YS, Yu F, et al. Oxidative stress and neuronal
death/survival signaling in cerebral ischemia. Mol Neurobiol. 2005; 31:105–116. [PubMed:
15953815]
76. Schouten JW. Neuroprotection in traumatic brain injury: a complex struggle against the biology of
nature. Curr Opin Crit Care. 2007; 13:134–142. [PubMed: 17327733]

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 23

77. Shreiber DI, Smith DH, Meaney DF. Immediate in vivo response of the cortex and the blood-brain
barrier following dynamic cortical deformation in the rat. Neurosci Lett. 1999; 259:5–8. [PubMed:
10027542]
78. Signoretti S, Marmarou A, Tavazzi B, Dunbar J, Amorini AM, Lazzarino G, Vagnozzi R. The
protective effect of cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following
experimental diffuse traumatic brain injury. J Neurotrauma. 2004; 21:1154–1167. [PubMed:
15453986]
79. Singh IN, Sullivan PG, Deng Y, Mbye LH, Hall ED. Time course of post-traumatic mitochondrial
oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications
for neuroprotective therapy. J Cereb Blood Flow Metab. 2006; 26:1407–1418. [PubMed:
16538231]
80. Smith DH, Meaney DF, Shull WH. Diffuse axonal injury in head trauma. J Head Trauma Rehabil.
2003; 18:307–316. [PubMed: 16222127]
81. Smith DH, Wolf JA, Lusardi TA, Lee VM, Meaney DF. High tolerance and delayed elastic
response of cultured axons to dynamic stretch injury. J Neurosci. 1999; 19:4263–4269. [PubMed:
10341230]
82. Stein SC, Spettell CM. Delayed and progressive brain injury in children and adolescents. Pediatr
Neurosurg. 1995; 23:299–304. [PubMed: 8743998]
83. Suehiro E, Ueda Y, Wei EP, Kontos HA, Povlishock JT. Posttraumatic hypothermia followed by
slow rewarming protects the cerebral microcirculation. J Neurotrauma. 2003; 20:381–390.
[PubMed: 12866817]
84. Sullivan BA, Hak LJ, Finn WF. Cyclosporine nephrotoxicity: studies in laboratory animals.
Transplant Proc. 1985; 17(4 Suppl. 1):145–154. [PubMed: 3895655]
85. Sullivan PG, Rabchevsky AG, Hicks RR, Gibson TR, Fletcher-Turner A, Scheff SW. Doseresponse curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats.
Neuroscience. 2000; 101:289–295. [PubMed: 11074152]
86. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition
in CNS trauma: cause or effect of neuronal cell death? J Neurosci Res. 2005; 79:231–239.
[PubMed: 15573402]
87. Sullivan PG, Thompson M, Scheff SW. Continuous infusion of cyclosporin A postinjury
significantly ameliorates cortical damage following traumatic brain injury. Exp Neurol. 2000;
161:631–637. [PubMed: 10686082]
88. Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial
dysfunction following traumatic brain injury. Exp Neurol. 1999; 160:226–234. [PubMed:
10630207]
89. Sullivan S, Friess SH, Ralston J, Smith C, Propert KJ, Rapp PE, Margulies SS. Behavioral deficits
and axonal injury persistence after rotational head injury are direction dependent. J Neurotrauma.
2013; 30:538–545. [PubMed: 23216054]
90. Sullivan S, Friess SH, Ralston J, Smith C, Propert KJ, Rapp PE, Margulies SS. Improved behavior,
motor, and cognition assessments in neonatal piglets. J Neurotrauma. 2013; 30:1770–1779.
[PubMed: 23758416]
91. Thompson HJ, Lifshitz J, Marklund N, Grady MS, Graham DI, Hovda DA, McIntosh TK. Lateral
fluid percussion brain injury: a 15-year review and evaluation. J Neurotrauma. 2005; 22:42–75.
[PubMed: 15665602]
92. Tsao PW, Ito S, Wong PY, Radde IC, Bryson S, Young DS, et al. Pharmacodynamics and
pharmacokinetics of cyclosporin A in the newborn pig. Dev Pharmacol Ther. 1992; 18:20–25.
[PubMed: 1483359]
93. Turner MS. Early use of intrathecal baclofen in brain injury in pediatric patients. Acta Neurochir
Suppl. 2003; 87:81–83. [PubMed: 14518529]
94. Verma G, Datta M. The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic
cell death. J Cell Physiol. 2012; 227:1791–1795. [PubMed: 21732347]
95. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth. 2007; 99:4–9.
[PubMed: 17573392]

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 24

96. Williams S, Raghupathi R, MacKinnon MA, McIntosh TK, Saatman KE, Graham DI. In situ DNA
fragmentation occurs in white matter up to 12 months after head injury in man. Acta Neuropathol
(Berl). 2001; 102:581–590. [PubMed: 11761718]
97. Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in
traumatic brain injury. Neurochem Int. 2006; 48:394–403. [PubMed: 16473439]

Brain Pathol. Author manuscript; available in PMC 2016 May 01.

Margulies et al.

Page 25

Figure 1.

Schematic of two head injury models. Focal injuries produced by controlled cortical impact
(CCI, top) and diffuse brain injuries produced by a sagittal rapid nonimpact rotation (RNR)
of the head (bottom). Representative coronal sections shown with regions of axonal injury
indicated with circles.
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Figure 2.

Tier 2 porcine intensive care cerebral perfusion pressure (CPP) management strategy.
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Figure 3.

Tier 1 overall positive outcome rates. Colored vertical bars indicating total positive outcome
response rates for each dose, the dark horizontal line indicating the underlying effectiveness
evaluation positive outcome rate threshold, the gray zone as the 5% beta error, and the bright
yellow line as the response rate threshold that must be met to achieve our effectiveness
evaluation targets with our small sample size and a 5% beta error. All doses at or exceeding
the yellow line meet the underlying positive outcome rate prescribed by our effectiveness
evaluation plan, and are defined as “successful” doses.
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Figure 4.

Tier 1 CsA dose–response findings.
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Table 1

Group size determination and power considerations.
n/group

Positive outcome rates
Controls

Total n = 20

Continuous measures

Treated

Difference

1.0%

32.7%

31.7%

10.0%

47.9%

37.9%

20.0%

62.5%

42.5%

95% CI

Effect size

95% CI

±22.8%

0.82σ

±0.47σ
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Table 2

Tier 1 subjects.
Pathology

Mitochondria

Excluded

1-h RNR

60

60

21

6-h RNR

50

50

12

1-h CCI

60

60

17

6-h CCI

50

50

7

220

220

57

Total

Abbreviations: RNR = rapid nonimpact rotation; CCI = controlled cortical impact.
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Table 3

Tier 1 overall positive outcome rates. Dose groups that achieve the required positive outcome rate to be
considered promising as defined by our Tier 1 effectiveness evaluation plan are shaded in yellow.
Group

Outcome

(Vehicle) 0 mg/kg/day

10 mg/kg/day

20 mg/kg/day

1-h RNR

Pathology

4/20

0/10

1/10

2/10
5/10

Mitochondria

6/10

4/10

6/20 (30%)

5/20 (25%)

Pathology

2/10

2/10

4/10

1/10

3/10

Mitochondria

5/10

7/10

6/10

5/10

6/10

7/20 (35%)

9/20 (45%)

10/20 (50%)

4/20

1/10

4/10

2/10
6/10

Pathology
Mitochondria

7/20 (35%)

6/20 (30%)

4/10
4/20 (20%)

9/20 (45%)
6/10

9/20

6/10

4/10

13/40 (33%)

7/20 (35%)

8/20 (40%)

Pathology

2/10

4/10

5/10

3/10

4/10

Mitochondria

5/10

7/10

4/10

3/10

5/10

6/20 (30%)

11/20 (55%)

9/20 (45%)

Total positive outcome rate
6-h CCI

0/10

10/20

Total positive outcome rate
1-h CCI

60 mg/kg/day

14/40 (35%)

Total positive outcome rate
6-h RNR

40 mg/kg/day

Total positive outcome rate

Abbreviations: RNR = rapid nonimpact rotation; CCI = controlled cortical impact.
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8/20 (40%)

6/20 (30%)

5/10
11/20 (55%)

9/20 (45%)

